Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes
This target trial emulation did not provide evidence for a substantial difference in cardiovascular outcomes between individuals with type 2 diabetes initiating semaglutide and dulaglutide.
Authors
- Timothy L. Lash (ORCID: https://orcid.org/0000-0002-5240-5195)
- Morten Schmidt (ORCID: https://orcid.org/0000-0002-4935-4059)
- Anthony Matthews (ORCID: https://orcid.org/0000-0002-1290-271X)
- Kasper Bonnesen (ORCID: https://orcid.org/0000-0002-8626-2372)
- Reimar W. Thomsen (ORCID: https://orcid.org/0000-0001-9135-3474)
- Diana Hedevang Christensen (ORCID: https://orcid.org/0000-0002-2693-5651)
- Uffe Heide‐Jørgensen (ORCID: https://orcid.org/0000-0002-8407-4618)
- Lars Pedersen (ORCID: https://orcid.org/0000-0002-9341-3888)
Institutions
- Emory University (US)
- Aarhus University (DK)
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Karolinska Institutet (SE)
- Regionshospitalet Herning (DK)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/pds.70276
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Aarhus Universitet
- Novo Nordisk
- Vetenskapsrådet
- Novo Nordisk Fonden